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Introduction
Coronary artery reperfusion is the only intervention that has
been shown to reduce the size of myocardial infarction.
Thrombolysis and PTCA are established methods to
achieve reopening of an occluded vessel in patients with
acute myocardial infarction [1–3]. Despite this observation,
ICAM-1 = intercellular adhesion molecule-1; PECAM-1 = platelet endothelial cell adhesion molecule-1; PTCA = percutaneous transluminal coro-
nary angioplasty; SK = streptokinase; tPA = tissue plasminogen activator; VCAM-1 = vascular cell adhesion molecule-1.
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Abstract
Background: Tissue damage after ischemia and reperfusion involves leukocyte endothelial interactions
mediated by cell adhesion molecules. This study was designed to determine the time course of soluble
adhesion molecules in patients with acute myocardial infarction after attempted reperfusion by
thrombolysis with tissue plasminogen activator (tPA) or streptokinase (SK), or percutaneous
transluminal coronary angioplasty (PTCA).
Methods: In 3 × 10 randomly selected patients with acute myocardial infarction undergoing
thrombolysis with tPA or SK, or treated with PTCA, plasma concentrations of soluble L-selectin,
P-selectin, E-selectin, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1
(VCAM-1) and platelet endothelial cell adhesion molecule-1 (PECAM-1) were measured by enzyme-
linked immunosorbent assay, 30 min and 1, 2, 4, 8, 12 and 24 hours after intervention.
Results: After thrombolysis with tPA, soluble L-selectin concentrations were persistently depressed
and soluble PECAM-1 concentrations were elevated, compared with controls, SK and PTCA. While
soluble VCAM-1 concentrations did not differ within the first hours after interventions between the
three groups, soluble VCAM-1 rose by 24 hours after tPA thrombolysis but did not increase after SK
and PTCA treatment. Soluble ICAM-1 concentrations were consistently elevated after PTCA
compared with controls and thrombolysed patients. Soluble E-selectin was depressed after tPA
thrombolysis and PTCA in comparison with controls, while the SK group showed an increase
throughout the observation period. Soluble P-selectin was increased after PTCA and SK lysis up to
8 hours after treatment compared with controls, but no significant differences could be found between
treatment groups.
Conclusion: Adhesion molecules mediating leukocyte endothelial interactions are altered subsequent
to postischemic reperfusion and by treatment with thrombolytic agents and angioplasty. The clinical
relevance of these biological changes remains to be determined.
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there has been concern that reperfusion itself may have
some deleterious effects on the myocardium by inducing an
acute inflammatory response, leading to a secondary reper-
fusion injury in addition to the ischemia-related injury [4,5].
Reperfusion of occluded vessels leads to an activation of
endothelial cells and an extravasation of leukocytes. This
consecutive extravasation is regulated by the sequential
interaction of adhesion molecules and their cognate ligands,
expressed by leukocytes, platelets, and endothelial cells. The
first contact between leukocytes and the vessel wall is estab-
lished by members of the selectin family of adhesion mole-
cules: L-selectin (CD62L), which is exclusively expressed by
leukocytes; P-selectin (CD62P), which can be found in
platelets and Weibel–Palade bodies of endothelial cells; and
E-selectin (CD62E), a transcriptionally regulated glycopro-
tein exclusively expressed by endothelial cells. After selectin-
mediated slowing down of the leukocytes, their firm adhesion
to the vessel wall involves the interaction between leukocyte
surface-expressed β2 or α4 integrins, and the members of
the immunoglobulin superfamily, ICAM-1 (CD54) and
VCAM-1 (CD106) [6–8]. Whereas ICAM-1 is expressed on
a broad variety of cells, VCAM-1 expression is restricted to
endothelial cells. After firm adhesion, leukocytes proceed to
transendothelial migration, which involves homotypic adhe-
sion mediated by PECAM-1 (CD31), that is expressed by
endothelial cells, platelets, and various leukocytes.
Soluble forms of adhesion molecules, such as sICAM-1,
sP-selectin and sE-selectin, have been the aim of several
previous studies. Increased levels were found in patients
with acute myocardial infarction or coronary artery disease
[9–17]. It is, however, still unknown what effects different
treatments aimed at the reopening of occluded coronary
arteries, such as thrombolysis or PTCA, may have con-
cerning these adhesion molecules.
The objective of this prospective controlled, non-random-
ized study was to investigate the early course of six differ-
ent adhesion molecules after myocardial infarction and
reopening therapy with thrombolysis or PTCA. Further-
more, the influence of singular thrombolytic agents should
be evaluated by comparing SK and tPA.
Materials and methods
Patients and therapy
All patients were admitted to the general medical intensive
care unit of a university hospital with the diagnosis of
acute myocardial infarction, based on a history of typical
chest pain and electrocardiographic changes according to
the Global Utilization of Streptokinase and t-PA for
Occluded Coronary Arteries (GUSTO-I) study [2]. In the
following, diagnosis was confirmed by typical elevation of
cardiac enzymes. The initial treatment consisted of three
different strategies and was based on the decision of the
initially attending emergency physician. The first strategy
was an intravenous thrombolysis with SK, 1.5 million IU
over 30 min. As a second protocol, patients received tPA
as the thrombolytic agent, according to the accelerated
regime [18] starting with a 15 mg bolus, followed by
0.75 mg/kg over 30 min, and then 0.50 mg/kg over the
next 60 min (tPA group). Both thrombolysis regimes were
started preclinically in the ambulance. For the third strat-
egy, patients underwent percutaneous transluminal coro-
nary angioplasty within 6 hours after the onset of chest
pain (PTCA group).
Within a period of 2 years, 10 patients were randomly
selected from each of the three treatment groups and
included in the study. The 30 patients were aged from 33
to 85 years (mean, 60 ± 14 years; 26 male, 4 female), and
concomitant treatment with acetylsalicylic acid and
heparin was identical in all three groups, according to the
GUSTO-I protocol [2]. Fourteen healthy individuals with a
similar pattern of age, gender, and body weight served as
control group for the assays. The protocol was approved
by the Institutional Review Board for Ethics and included
the informed consent of all patients.
Blood samples
Samples from all patients were taken immediately after
thrombolysis or angioplasty, and then 1, 2, 4, 8, 12 and
24 hours after treatment. Plasma was obtained by cen-
trifugation at 4°C, at 3000 rpm for 10 min. Samples
were stored at –80°C before measurement of plasma
levels of the soluble forms sE-selectin, sL-selectin, sP-
selectin, sICAM-1, sVCAM-1, and sPECAM-1 using
commercially available enzyme-linked immunosorbent
assays (ELISAs) (R&D Systems Europe, Abingdon, UK).
Blood samples of 14 healthy volunteers served as con-
trols and were centrifuged, stored and measured in the
same way as already described.
To investigate direct interactions of tPA or SK with the
ELISA, additional measurements were performed after in
vitro incubation of control samples with SK (250 U/ml)
and tPA (1 µg/ml) at therapeutical concentrations [19,20]
for 30 min.
Clinical data
On admission, the patients’ clinical status was assessed,
including age, sex, height, weight, and time from onset of
clinical symptoms until start of treatment. Complications,
especially postinfarctial angina pectoris, arrhythmia (ie
ventricular tachycardia, ventricular fibrillation), hypotension
(systolic blood pressure < 90 mmHg), renal failure (urea
> 50 mg/dl, creatinine > 2 mg/dl), and cerebral ischemia
or hemorrhage were recorded at hospital discharge.
Statistics
Differences between the three treatment groups were
tested with the Kruskal–Wallis test, and differences
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between treatment groups and native controls were tested
with the Mann–Whitney U test at each point of time. The
significance of intra-individual changes during the obser-
vation period was examined using Friedman’s test. Differ-
ences between native and supplemented (tPA, SK)
control samples were explored by Wilcoxon rank sum test.
Fisher’s exact test was used to analyse nominal clinical
data. P < 0.05 defined significance.
Results
Demography
The clinical characteristics of the 30 patients with acute
myocardial infarction showed no significant differences
between the groups concerning sex, age, height, weight,
time until onset of therapy, and rate of complications (data
not shown).
Measurements
Impact of in vitro incubation on soluble adhesion molecule
measurements
Incubation with tPA or SK resulted in a small but significant
decrease of sE-selectin concentrations, from 29.3 ± 2.2 to
28.1 ± 2.0 or 24.8 ± 2.4 ng/ml, respectively. The concen-
tration of sL-selectin increased significantly (from
998.0 ± 64.7 to 1080.8 ± 79.3 or 1053.2 ± 67.7 ng/ml,
respectively) and that of sICAM-1 decreased significantly
(from 230.2 ± 15.9 to 183.6 ± 12.5 or 182.4 ± 12.2 ng/ml,
respectively). In vitro incubation with tPA caused a signifi-
cant decrease of sVCAM-1 concentrations (from
403.4 ± 22.4 to 367.8 ± 25.7 ng/ml), whereas SK did not
affect sVCAM-1 concentrations. Both the sPECAM-1 and
sP-selectin concentrations did not show significant
changes after in vitro incubation with tPA or SK.
sE-selectin (Fig. 1a)
PTCA as well as tPA lysis led to lower sE-selectin levels in
comparison with healthy controls. This decrease was,
however, much more pronounced than the decrease after
in vitro incubation, resulting in a significant difference
between supplemented control samples and samples of
patients treated with lytic agents. The declension of
sE-selectin in the tPA patients remained significant during
the whole observation period. No increasing or decreasing
intra-individual trends could be observed, either in the tPA
group or in the PTCA group. SK patients, in contrast,
revealed increasing sE-selectin levels; significance,
however, was failed. There were also no differences of
sE-selectin levels between the three treatment groups.
sL-selectin (Fig. 1b)
Analysis of sL-selectin showed similar results. Plasma
levels in the tPA group were significantly decreased in
comparison with control samples as well as in comparison
with the other treatment groups. In contrast, levels of the
other treatment groups did not differ significantly from
controls. No decreasing or increasing intra-individual
changes could be found. Direct interactions of tPA or SK
with the assays were not responsible for the observed
phenomena, confirmed by the in vitro assays.
sP-selectin (Fig. 1c)
Plasma levels of all treatment groups were elevated com-
pared with controls; elevation of sP-selectin in samples of
patients undergoing SK lysis or PTCA reached a level of
significance during the first 8 hours after treatment. Analysis
of intra-individual changes indicated a significant decrease
in both the SK and PTCA groups. No significant differences
could be found between the three treatment groups.
sVCAM-1 (Fig. 2a)
The sVCAM-1 plasma concentrations were elevated in all
treatment groups compared with healthy controls. Only
the tPA group, however, reached a level of significance.
The tPA patients also showed an intra-individual increase,
which only just failed to be significant (P = 0.06) in Fried-
man analysis, but reached the level of significance in com-
parison with the other therapies 12 and 24 hours after
treatment. Direct interactions of tPA or SK with the assays
were not responsible for the observed phenomena; this
was confirmed by the in vitro assays.
sPECAM-1 (Fig. 2b)
Plasma of patients undergoing tPA lysis showed signifi-
cantly increased sPECAM-1 concentrations compared
with controls, while SK lysis and PTCA did not cause any
differences. Investigation of intra-individual changes and
differences between the treatment groups did not
produce any significant results.
sICAM-1 (Fig. 2c)
In patients undergoing PTCA, sICAM-1 levels were signifi-
cantly elevated in comparison with controls and patients
with tPA or SK lysis, whereas no intra-individual changes
could be found. The changes observed were not due to
direct interactions of tPA or SK with the assays, as con-
firmed by the in vitro assays.
Discussion
Soluble forms of adhesion molecules including selectins
and members of the immunoglobulin family, most of which
are generated by alternative splicing, are considered to be
indicators of an activation of endothelial cells, platelets or
leukocytes [5,21,22]. They have been shown to increase in
patients with acute coronary syndrome, after atherosclerotic
plaque rupturing, as well as in ischemic and reperfused
areas (eg after receiving revascularization therapy with
PTCA or lysis).
In this study, we found significantly reduced levels of sL-
selectin in the tPA group compared with the controls, as
well as compared with patients from the SK and PTCA
groups. L-Selectin undergoes rapid cleavage at the cell
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surface following the leukocyte’s activation, resulting in the
generation of soluble L-selectin. Whereas several cytokines,
notably tumor necrosis factor-α, undergo processing similar
to L-selectin, this mode is unique to L-selectin among
adhesion molecules of the selectin or immunoglobulin
families, and results in baseline soluble L-selectin concen-
trations exceeding those of any other soluble adhesion
molecule. Low soluble L-selectin concentrations have
been observed in patients at risk for acute respiratory dis-
tress syndrome [23], in a number of ventilated intensive
care patients [24,25], and in ischemic heart disease [26].
Reduced soluble L-selectin concentrations may result
from de novo expression of L-selectin ligands that
sequester circulating L-selectin [23]. The low L-selectin
concentrations observed after tPA may therefore hint to
expression of such ligands, although their molecular
nature remains to be defined.
The concentration of sVCAM-1 rose by 24 hours after tPA
lysis, whereas sVCAM-1 concentrations did not differ
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Figure 1
Soluble E-selectin (a), soluble L-selectin (b) and soluble P-selectin (c)
levels in patients with acute myocardial infarction compared with healthy
controls. Data of patients are shown as mean and SEM, and data of
controls (grey area) are shown as mean and 95% confidence interval.
Figure 2
Soluble VCAM-1 (a), soluble PECAM-1 (b) and soluble ICAM-1 (c)
levels in patients with acute myocardial infarction compared with healthy
controls. Data of patients are shown as mean and SEM, and data of
controls (grey area) are shown as mean and 95% confidence interval.
within the first hours after interventions between the three
groups. The sE-selectin level was depressed after tPA and
PTCA in comparison with controls, whereas the SK group
showed an increase throughout the observation period.
VCAM-1 and E-selectin are adhesion molecules exclusively
expressed by endothelial cells. Their soluble isoforms have
been reported elevated in patients with unstable angina,
documented coronary artery disease, or in patients with
essential hypertension [27–31]. Whereas previous studies
found no effect of thrombolytic therapy with tPA or SK on
circulating VCAM-1 and E-selectin during the first 24 hours
after attempted reperfusion [32], we observed a gradual
increase at 12–24 hours for VCAM-1 after tPA and for E-
selectin after SK lysis. As both adhesion molecules are
transcriptionally regulated, this slow increase is in accor-
dance with a protracted course of events following reperfu-
sion that may well extend beyond 24 hours.
Furthermore, we found significantly elevated serum levels
for sICAM-1 after PTCA and for sPECAM-1 in the tPA
group compared with controls and with both of the other
therapy groups. No obvious differences between the three
therapy groups emerged for sP-selectin, but sP-selectin
was increased after PTCA and SK up to 8 hours after treat-
ment compared with controls. Caution has to be exerted
when interpreting circulating isoform concentrations
because various cell types express ICAM-1, PECAM-1 and
P-selectin. In patients with acute myocardial infarction,
unstable angina, and after coronary spasm, increased
levels of sP-selectin have been reported [9,12,33,34].
Soluble ICAM-1 and PECAM-1 have reported to be ele-
vated in patients with coronary artery disease or acute
myocardial infarction [11,16,35–37]. Both soluble ICAM-1
and PECAM-1 have been reported released into the circu-
lation following reperfusion after acute myocardial
ischemia, resulting in a transient increase within the first
hours after reperfusion [28,32]. In the present study, we
found both ICAM-1 and PECAM-1 remarkably stable after
attempted reperfusion, but ICAM-1 was consistently ele-
vated for 24 hours after PTCA whereas PECAM-1 was ele-
vated between 1 and 12 hours after tPA.
Our findings are therefore in accordance with previous
observations in finding changed levels of adhesion mole-
cules, probably indicating endothelial activation as a result
of reperfusion of the ischemic myocardium. Limitation of
this study is the lack of samples taken before start of treat-
ment, and some uncertainty is added to the interpretation
of our results because serum levels of the soluble adhesion
molecules are not only influenced by their synthesis and
shedding, but also by their clearance or uptake by counter-
receptors. Direct interactions of SK or tPA with the assays
were not responsible for the observed changes.
Adhesion molecules mediating leukocyte endothelial inter-
actions undergo complex changes in patients treated for
acute myocardial infarction. Both postischemic reperfu-
sion and the specific treatment modality chosen appear to
be involved in the regulation of these adhesion molecules.
Elucidation of the clinical relevance of altered adhesion
molecules awaits larger studies with later endpoints.
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